Disease Detail

ID DOID:285
Name hairy cell leukemia
Definition A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphocytic leukemia chronic lymphocytic leukemia hairy cell leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ibrutinib hairy cell leukemia not applicable detail...
BRAF V600E Vemurafenib hairy cell leukemia sensitive detail...
Unknown unknown Fenretinide hairy cell leukemia not applicable detail...
BRAF V600E N/A hairy cell leukemia not applicable detail...
Unknown unknown Moxetumomab pasudotox-tdfk hairy cell leukemia not applicable detail...
BRAF V600E MAP2K1 K57T Vemurafenib hairy cell leukemia predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT01711632 Phase II Vemurafenib BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Active, not recruiting
NCT01841723 Phase II Ibrutinib Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Recruiting
NCT01905813 Phase I INCB040093 + Itacitinib INCB040093 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting
NCT03410875 Phase II Obinutuzumab + Vemurafenib A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Recruiting
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting